Rising PSA With a Negative PSMA Scan — What Now?

Not necessarily. A negative result at a low PSA means the scan did not find visible disease at this point — it does not rule out microscopic deposits that are too small to detect. EAU and ASCO guidance is explicit about this: a negative PSMA PET-CT in the setting of biochemical recurrence does not equal absence of disease. Your oncologist will continue to monitor your PSA and advise on next steps based on how it behaves over time.

Not at the same PSA level, in most cases. Repeating the scan before your PSA has risen to a level where detection rates improve is unlikely to give a different result, because the deposit size has not changed. Your oncologist will advise when rescanning becomes worthwhile — usually once PSA has risen further or your clinical picture has changed in some other way. Timing is a clinical judgement, not a fixed interval.

Yes, in many cases. EAU guidance supports empirical salvage radiotherapy to the prostate bed in patients with biochemical recurrence after surgery, even without a confirmed site on imaging. The decision depends on how quickly your PSA is rising, your original pathology, and your general fitness. This is one of the reasons a negative scan is not the end of the clinical picture — ask your oncologist directly whether you are a candidate and what the expected outcome is.

PSA doubling time is how long it takes for your PSA to double from one measurement to the next. A short doubling time — meaning PSA is rising quickly — suggests more aggressive behaviour and changes the urgency of your team's decisions, even when the absolute PSA level is still low. It is one of the most important pieces of information when imaging has not confirmed a site of recurrence, because it tells your team how much time there may be before the disease becomes detectable or symptomatic.

Yes, and this is exactly what EAU and ASCO guidance accounts for. PSMA PET-CT is highly sensitive but cannot detect deposits below a certain size. This is not a problem specific to your scan centre or scanner — it is a known property of the technology at low PSA values. Your team will factor that uncertainty into their monitoring plan and into the PSA threshold at which they recommend rescanning or starting treatment.

PSMA PET-CT is available through CION partner imaging centres at an indicative price of ₹23,999. This is a guide figure as of the time of writing — confirm the current price and tracer availability when you book, as supply and scheduling can vary. CION coordinates the referral and the scan report is reviewed alongside your clinical history by your treating team.